Shah Capital has ended its attempts to exert influence over vaccine developer Novavax, bringing more than years of activism ...
On paper, the programme was built. In practice, many never crossed the finish line. Demand was not the problem. In a June ...
The immunology alliance follows a collaboration between the UK Biobank and the University of Exeter, supported by the Novo ...
Pharmaceutical supply chains have more data at their fingertips than ever before. The challenge is turning that information into foresight. From temperature monitoring devices and connected containers ...
Swiss biotech Nouscom has closed a €120 million ($135 million) fourth-round financing for a vaccine to protect people with a ...
A large-scale observational study has suggested that smartphones and watches may be able to spot mild cognitive impairment (MCI) during daily usage. The results of the Intuition Brain Health study – ...
GSK has joined a lengthening list of companies that have paused diversity, equity, and inclusion (DEI) targets under pressure from US President Donald Trump. The company has indicated that it is ...
Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access scheme ...
According to an update on the clinicaltrials.gov registry website, Novartis has terminated the study of Fabhalta (iptacopan) ...
NICE has said that four artificial intelligence technologies can be deployed by the NHS to detect fractures on X-rays in urgent care, while more evidence on their value is generated, but has limited ...
Hundreds of people with a rare and aggressive form of leukaemia will be able to access a CAR-T therapy developed by UK biotech Autolus after it was recommended for routine commissioning by the NHS.
Vinay Prasad has stepped down as head of the FDA's Center for Biologics Evaluation and Research (CBER), less than three months after taking on the role. His departure – first reported by STAT and now ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results